In short
Clinical trials are studying Lidocaine Hydrochloride in different patient groups, including surgery patients, people with pain crises, and patients in intensive care. These trials mainly look at pain control, recovery, opioid use, and other safety or effectiveness outcomes. The studies are in several phases, mostly Phase 2 and Phase 3.
Key points
- Clinical trials of Lidocaine Hydrochloride are being done in many settings, especially surgery, intensive care, and severe pain states. Most studies are Phase 3, with some Phase 2 trials, and they include patients with sickle cell disease, stroke, cardiac surgery, fractures, headache after bleeding in the brain, and other procedure-related pain. The main goals are to lower pain, reduce opioid use, improve recovery, and measure procedure success or blood drug levels. Some trials compare Lidocaine Hydrochloride with placebo, saline, or other local anesthetics. The studies use outcomes such as pain scores, opioid consumption, recovery scores, and inflammatory markers.
Trial overview
These trials study Lidocaine Hydrochloride in many clinical settings, mainly for pain control, anesthesia, and recovery after procedures. The studies include both completed and authorised trials, and most are interventional, meaning the researchers give a treatment and measure the result.
The trial data show use in sickle cell disease, surgery, headache after subarachnoid hemorrhage, acute ischemic stroke, intensive care, and other procedure-related pain settings. Some studies also compare Lidocaine Hydrochloride with saline, placebo, or other local anesthetics.
Conditions being studied
One important group of trials studies pain during vaso-occlusive crisis in sickle cell disease, which is a painful blockage of blood flow in small vessels. These studies look at whether Lidocaine Hydrochloride can reduce opioid use during severe pain episodes.
Several trials focus on surgery-related pain, including open hepatectomy, hand and foot surgery under WALANT, tonsillectomy, breast surgery, and pleural drainage in intensive care. Other studies look at pain after distal radius fracture reduction, dental procedures, perineal tears, and oral mucositis in head and neck cancer.
Some trials study more specific clinical problems, such as headache after spontaneous subarachnoid hemorrhage, postoperative pain after intracranial surgery, and comfort during mechanical thrombectomy for acute ischemic stroke. One study also examines the drug in young and elderly patients to compare pharmacokinetics, which means how the body handles the medicine.
Who may take part
The target populations are very different across the trials, so eligibility depends on the condition and the procedure being studied. Examples include patients with sickle cell disease, adults undergoing cardiac surgery, children having cataract surgery, and people with acute fracture reduction or intensive care procedures.
Some studies are limited to people with a very specific problem, such as opioid-tolerant individuals, patients with chronic tonsillitis, or women with first-degree perineal tears after delivery. Other trials include broader surgical groups, such as patients having open hepatectomy, robotic bariatric surgery, or subpectoral cardiac device implantation.
Enrollment ranges from very small studies to large multicenter trials, showing that the research includes both early focused testing and larger confirmation studies.
Trial phases and study designs
Most of the Lidocaine Hydrochloride trials in the data are Phase 3 studies, which usually test whether a treatment works in larger groups and compare it with standard care or another treatment. There are also Phase 2 studies, which often look at early signs of benefit and safety in smaller groups.
Several studies are described as randomized, double-blind, or controlled, which are study methods that help make the results more reliable. A randomized study assigns people by chance, and a double-blind study keeps participants and researchers from knowing which treatment is given.
Some trials compare Lidocaine Hydrochloride with saline or placebo, while others compare it with another local anesthetic such as ropivacaine or with different ways of giving anesthesia. A few studies are low-intervention trials, which means the study adds little beyond usual care.
Main endpoints measured
The most common endpoint is pain relief, measured with tools such as the Visual Analog Scale (VAS), the Numerical Pain Rating Scale (NPRS), or related pain scores. These scales help patients rate pain in a simple numerical way.
Some studies measure opioid use, such as total morphine consumption or cumulative opioid dose, because reducing opioid need is an important goal in several trials. Other studies measure recovery scores, such as the Quality of Recovery 15 (QoR-15), or the need for rescue treatment after the procedure.
Additional endpoints include blood levels of inflammatory markers like interleukin-6 (IL-6), plasma concentration of lidocaine, success of nerve block, and time to breakthrough pain or to hospital recovery milestones. Some studies also track clinical response, treatment failure, or postoperative complications such as nausea, low oxygen levels, or bowel slowing.
Main comparisons in the studies
Many trials compare Lidocaine Hydrochloride with a control treatment such as sodium chloride solution, which acts as a comparison fluid. This helps researchers see whether the active treatment performs better than no active drug in the same setting.
Other trials compare Lidocaine Hydrochloride with another local anesthetic, such as ropivacaine or bupivacaine, to see which option gives better pain control or recovery. In some studies, Lidocaine Hydrochloride is part of a larger anesthesia plan, where the question is whether it can reduce opioid use or improve postoperative comfort.
A few studies use Lidocaine Hydrochloride in special procedures, such as nerve blocks, infiltration around wounds, subcutaneous injection, or intravenous infusion, depending on the clinical question being tested.
What these trials may mean for patients
For patients, these studies are trying to find better ways to control pain, support recovery, and reduce the need for opioids in many different medical situations. The results may help guide future care in surgery, emergency treatment, intensive care, and chronic pain-related procedures.
Because the trials study many different conditions, the findings do not apply to one single disease. Instead, they show how Lidocaine Hydrochloride is being tested across several patient groups and procedures to see where it may be most useful.